Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING Phase 2

Omega-3D: Omega-3 for Diet-Driven Health Disparities

NCT07078344 · View on ClinicalTrials.gov ↗

Study Summary

The goal of this clinical trial is to learn whether omega-3 fatty acid supplementation can reduce inflammation-related biomarkers and improve cardiovascular health in healthy adult volunteers with different genetic backgrounds. The main questions it aims to answer are: Does the response to omega-3 supplementation differ based on genetic variation in the FADS gene cluster (specifically rs174537)? Are changes in fatty acid ratios and inflammation markers greater among individuals of African ancestry compared to those of European ancestry? Researchers will compare omega-3 supplements to a placebo in a randomized, placebo-controlled crossover study to determine whether the Omega-3 supplementation is more effective in certain genetic and ancestry groups. Participants will take omega-3 supplements or a placebo daily for a defined period, then cross over to the other intervention. They will provide blood samples for analysis of fatty acid levels and inflammatory markers, complete questionnaires, and attend scheduled study visits.

Interventions

  • DIETARY_SUPPLEMENT Omega-3 Fatty Acids and Safflower Oil Placebo
  • DIETARY_SUPPLEMENT Safflower Oil Placebo and Omega-3 Fatty Acids

Study Locations (2)

Arizona

  • Arizona Cancer Center — Tucson

District of Columbia

  • Georgetown University — Washington D.C.

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2025-07-31
Est. Completion 2029-12-31
Phase Phase 2

Sponsor

University of Arizona

379 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07078344

The ClinicalTrials.gov registry entry for NCT07078344 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 379 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 2 interventions — of which Omega-3 Fatty Acids and Safflower Oil Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT07078344 reports 2 study locations spanning 2 distinct geographic areas — top geographies include Arizona, District of Columbia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT07078344 about?

NCT07078344 is a clinical study titled "Omega-3D: Omega-3 for Diet-Driven Health Disparities". The goal of this clinical trial is to learn whether omega-3 fatty acid supplementation can reduce inflammation-related biomarkers and improve cardiovascular health in healthy adult volunteers with different genetic backgrounds. The main questions it aims to answer are: Does the response to omega-3 s...

What is the current status of trial NCT07078344?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2025-07-31. Estimated completion is 2029-12-31.

What conditions does trial NCT07078344 study?

This clinical trial studies the following conditions: Cardiovascular Diseases, Heart Health Markers, Omega 3 Fatty Acids. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT07078344?

The interventions under investigation include: Omega-3 Fatty Acids and Safflower Oil Placebo (DIETARY_SUPPLEMENT), Safflower Oil Placebo and Omega-3 Fatty Acids (DIETARY_SUPPLEMENT). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT07078344?

This trial is sponsored by University of Arizona, which has 379 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT07078344 being conducted?

This trial has 2 study locations across Arizona, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial